Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | FER | P16591 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MARK3 | P27448 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181661 | 0.91 | KIF11 (0.46) | JAK2TTKKIF11CYP2A6HPGD | |
| SCHEMBL29955660 | 0.91 | KIF11 (0.46) | JAK2TTKKIF11CYP2A6HPGD | |
| SCHEMBL182633 | 0.86 | JAK2 (0.63) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| Hydrochloric Acid SCHEMBL730582 | 0.84 | JAK2 (0.61) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| Hydrazine SCHEMBL5316054 | 0.82 | JAK2 (0.65) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| Tert-Butyl Formate SCHEMBL27702956 | 0.80 | PDPK1 (0.46) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL22513720 | 0.79 | JAK2 (0.50) | PDPK1JAK2DYRK1ACLK4PRKD3 | |
| SCHEMBL29953542 | 0.78 | KIF11 (0.46) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL15652140 | 0.78 | TTK (0.52) | PDPK1JAK2CDK2TTKKIF11 | |
| SCHEMBL182436 | 0.78 | KIF11 (0.46) | PDPK1JAK2DYRK1AFLT3CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | PDPK1 684/4885JAK2 13/4885DYRK1A 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.